The company sold approximately 9.4 million shares to reach that $15 floor, failing to gain momentum after an opening trade of $14.70. This lackluster performance underscores the current volatility facing clinical-stage biotechnology firms as they attempt to navigate public markets. The decline reflects a cautious reception for the developer, which had aimed for a higher valuation during its initial offering process.